Rhythm Pharmaceuticals (RYTM) Stock Price & Analysis
RYTM Stock Chart & Stats
- Day’s Range
- MXN 1,860.00 - MXN 1,860.00
- 52-Week Range
- MXN 1,500.00 - MXN 2,100.00
- Previous Close
- MXN 1,593.54
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 144.98B
- Enterprise Value
- MXN 6.47B
- Total Cash (Recent Filing)
- MXN 320.94M
- Total Debt (Recent Filing)
- MXN 3.52M
- Price to Earnings (P/E)
- ―
- Beta
- 0.47
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- -45.94
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Commercial Traction
Strong product adoption is visible in both revenue and patient metrics, reducing reliance on a single early launch signal. Continued growth in reimbursed patients can support recurring prescription demand and strengthen the commercial foundation over the next several quarters.
Attractive Product Economics
The combination of a multi-year revenue ramp and consistently high gross margins indicates attractive economics for IMCIVREE at the product level. If commercial growth continues, these margins provide substantial capacity to fund selling, development, and market expansion.
Pipeline And Market Expansion
The company is building growth beyond its current approved business through additional indications and geographic expansion. Phase III plans, Japan commercialization, and upcoming European launches create multiple potential drivers of durable demand rather than dependence on one market alone.
Bears Say
Persistent Unprofitability
Rhythm has not yet converted strong gross profitability into sustainable company-wide earnings. The deeply negative net margin means continued execution depends on scaling revenue faster than operating costs, leaving earnings vulnerable if expansion expenses remain elevated.
Ongoing Cash Consumption
Negative operating and free cash flow show that the business still consumes substantial cash while expanding. Although quarterly cash use was lower and operating cash flow improved year over year, persistent burn can limit flexibility and increase reliance on financing.
Large License Payments
The amended LG Chem agreement lowers the prospective royalty rate but creates sizable contractual cash obligations before the pipeline is proven commercially. These payments compete with research, commercialization, and other capital needs during a loss-making period.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
What is Rhythm Pharmaceuticals’s market cap?
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
How were Rhythm Pharmaceuticals’s earnings last quarter?
Is Rhythm Pharmaceuticals overvalued?
Does Rhythm Pharmaceuticals pay dividends?
What is Rhythm Pharmaceuticals’s EPS estimate?
How many shares outstanding does Rhythm Pharmaceuticals have?
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Rhythm Pharmaceuticals Stock Smart Score
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Meeker
- Employees
- 414
- Website
- www.rhythmtx.com
- Address
- 222 Berkeley Street, Boston, MA, 02116, US
Rhythm Pharmaceuticals (RYTM) Earnings & Revenues
RYTM Company Deck
RYTM Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, led by 29% sequential revenue growth, a solid U.S. acquired HO launch, improving payer coverage, strong prescriber and reimbursed-patient trends, the Japan launch, and progress toward phase III studies in acquired HO and Prader-Willi syndrome. The company also reported substantial liquidity and expanded financing flexibility. Offsetting factors included a GAAP loss, higher R&D spending, the operational limitation of Japan's two-week prescription supply during its first year, ongoing physician-education and diagnosis work, and significant payments associated with the LG Chem amendment. Highlights significantly outweighed the lowlights.
View all MX:RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
